Alpha-MSH vs PEG-MGF

Melanocortin peptide; activates MC1R (pigmentation/anti-inflammatory), MC3R (energy balance), MC4R (appetite); suppresses NF-κB and pro-inflammatory cytokines

α-Melanocyte-stimulating hormone (α-MSH) is an endogenous 13-amino-acid peptide derived from proteolytic processing of proopiomelanocortin (POMC) that acts through melanocortin receptors (MC1R–MC5R), with biological roles including skin pigmentation, anti-inflammatory signaling, thermoregulation, and energy homeostasis. Its anti-inflammatory actions are mediated principally through MC1R and MC3R activation, leading to inhibition of NF-κB-dependent cytokine production, reduction of pro-inflammatory mediators including IL-1β and TNF-α, and modulation of leukocyte activity in both peripheral and central nervous system compartments. Research published in the Annals of the New York Academy of Sciences has characterized the mechanisms of α-MSH's anti-inflammatory activity in vivo and in vitro, and subsequent work has described new insights into its immunomodulatory functions and therapeutic potential in inflammatory conditions. α-MSH is a research compound with no FDA approval for any indication; no human clinical trials have established safety or efficacy for exogenous α-MSH administration in anti-inflammatory, neuroprotective, or other therapeutic contexts. Alpha-MSH and the melanocortin peptide family α-MSH is the prototype endogenous ligand for the melanocortin receptor family — five receptors (MC1R–MC5R) with distinct tissue distribution and functions. The pharmacological development of synthetic melanocortin analogues has produced several clinically and commercially relevant compounds derived from or inspired by α-MSH: Melanotan I (afamelanotide, MC1R-selective, approved as Scenesse for erythropoietic protoporphyria), Melanotan II (non-selective, superpotent, never approved; extensively used in research), and PT-141/bremelanotide (cyclized Melanotan II analogue, FDA-approved as Vyleesi for female hypoactive sexual desire disorder via MC3R/MC4R). α-MSH itself serves as the structural reference point for this lineage — the pharmacophore binding sequence (His-Phe-Arg-Trp) shared by all active melanocortin analogues is derived from α-MSH residues 6–9. Appetite regulation and obesity research: α-MSH's role in energy homeostasis is mediated through MC4R activation in the hypothalamus, where it acts as an endogenous satiety signal opposing the appetitive effects of AgRP (agouti-related protein). Loss-of-function MC4R mutations are the most common monogenic cause of severe early-onset obesity, establishing the α-MSH/MC4R pathway as a validated target for pharmacological weight management. Setmelanotide (Imcivree), an MC4R agonist, is FDA-approved for obesity caused by MC4R pathway deficiency mutations (POMC deficiency, PCSK1 deficiency, leptin receptor deficiency) — a direct pharmacological descendant of the α-MSH mechanism.

Pegylated form of MGF; activates muscle stem cells (satellite cells) to repair and regenerate muscle tissue after damage

PEG-MGF (pegylated mechano growth factor) is a synthetic derivative of mechano growth factor (MGF, IGF-1Ec), in which the bioactive C-terminal E-peptide domain of the IGF-1 gene splice variant is chemically conjugated with polyethylene glycol (PEG) to improve aqueous stability and extend its proposed in vivo half-life relative to the rapidly degraded unmodified peptide. PEGylation is intended to preserve the proposed satellite cell-activating and tissue repair-promoting actions of the native MGF E-peptide over a longer post-administration window, with the pharmacological rationale extrapolated from preclinical and in vitro research on the parent MGF compound. No indexed peer-reviewed literature has been identified for PEG-MGF as a distinct chemical entity under its common name or under pegylated IGF-1 splice variant terminology in the biomedical literature, and the compound does not appear in PubMed with characterized pharmacokinetic or pharmacodynamic properties. PEG-MGF has no regulatory approval in any jurisdiction and no published human pharmacokinetic, safety, or efficacy data; it is sold as a research chemical by vendors without an evidence base establishing its biological activity as a defined and characterized therapeutic agent.